albireo pharma ipsen：近10億美元收購後開花結果！ Ipsen罕見兒科肝病藥獲批新 ...
近10億美元收購後開花結果！ Ipsen罕見兒科肝病藥獲批新 ...
2023年6月14日—法國生技公司Ipsen在今年1月以9.52億美元，收購罕病療法公司AlbireoPharma後，近(13)日，原Albireo的核心產品Bylvay(odevixibat)再獲美國食品藥物管理 ...。其他文章還包含有：「IpsentoAcquireAlbireo」、「AcquisitionofAlbireohasbeencompleted」、「IpsencompletesacquisitionofAlbireo」、「IpsenacquiertAlbireo」、「Ipsenpays$952MtoacquireAlbireoandliverdisease...」、「IpsenconcludespurchaseofAlb...
查看更多 離開網站
Ipsen to Acquire Albireo
https://www.ipsen.com
Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
Acquisition of Albireo has been completed
https://www.ipsen.com
Ipsen has completed its acquisition of Albireo, expanding the scope of its rare disease portfolio.
Ipsen completes acquisition of Albireo
https://ml-eu.globenewswire.co
The acquisition enriches Ipsen's Rare Disease portfolio, with promising therapeutics for pediatric and adult rare cholestatic-liver diseases, ...
Ipsen acquiert Albireo
https://www.ipsen.com
Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
Ipsen pays $952M to acquire Albireo and liver disease ...
https://www.fiercepharma.com
Ipsen is set to acquire rare disease specialist Albireo for $952 million. The AZ spinout is developing drugs to treat pediatric liver ...
Ipsen concludes purchase of Albireo Pharma
https://www.pharmaceutical-tec
French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma, expanding its rare disease portfolio.
Ipsen to Acquire Albireo for Rare Disease Portfolio
https://www.biospace.com
French biopharma Ipsen has agreed to acquire Boston-based Albireo Pharma for $42 per share, plus a contingent value right of $10 per share.
The acquistion of Albireo
https://www.ipsen.com
Ipsen must deal with or may have to deal with competition from generic medicines that may result in market-share losses, which could affect its ...
After Albireo buyout
https://www.fiercepharma.com
After Ipsen made a splash at this year's JPM conference, the centerpiece of its Albireo buyout, Bylvay, has won a coveted label expansion.